Claire Manuszak, BS, discusses a phase I study (NCT03495323) with prexasertib (LY2606368) and LY3300054 in ovarian cancer.
Claire Manuszak, BS
Advertisement
Articles by Claire Manuszak, BS
Claire Manuszak, BS, discusses the rationale to combine prexasertib (LY2606368) and LY3300054 in patients with high-grade serous ovarian cancer.
Advertisement
Latest Updated Articles
The Rationale to Combine Prexasertib With LY3300054 in Ovarian CancerFebruary 10th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
3
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
4
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
5